These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20061136)

  • 1. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
    van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
    Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
    Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
    Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
    Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
    J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
    Chen E; Jonker D; Gauthier I; MacLean M; Wells J; Powers J; Seymour L
    Clin Cancer Res; 2009 Feb; 15(4):1481-6. PubMed ID: 19228749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
    Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
    Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
    Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
    Duran I; Hotté SJ; Hirte H; Chen EX; MacLean M; Turner S; Duan L; Pond GR; Lathia C; Walsh S; Wright JJ; Dancey J; Siu LL
    Clin Cancer Res; 2007 Aug; 13(16):4849-57. PubMed ID: 17699864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
    Fakih MG; Trump DL; Muindi JR; Black JD; Bernardi RJ; Creaven PJ; Schwartz J; Brattain MG; Hutson A; French R; Johnson CS
    Clin Cancer Res; 2007 Feb; 13(4):1216-23. PubMed ID: 17317832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
    Fiedler W; Mesters R; Heuser M; Ehninger G; Berdel WE; Zirrgiebel U; Robertson JD; Puchalski TA; Collins B; Jürgensmeier JM; Serve H
    Leuk Res; 2010 Feb; 34(2):196-202. PubMed ID: 19674789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
    Trarbach T; Schultheis B; Gauler TC; Schneider V; Strumberg D; Eberhardt WE; Le Scouiller S; Marotti M; Brown KH; Drevs J
    Invest New Drugs; 2012 Oct; 30(5):1962-71. PubMed ID: 21989836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
    van Herpen CM; Lassen U; Desar IM; Brown KH; Marotti M; de Jonge MJ
    Anticancer Drugs; 2013 Feb; 24(2):204-11. PubMed ID: 23197081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
    Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
    J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
    Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
    Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.